AI总结
核心结论
Sam Altman虽在OpenAI无直接股权，但其庞大的个人投资组合与OpenAI业务深度交织，引发了监管机构对其潜在利益冲突的审查。
结构逻辑
- 背景：Altman的广泛投资网络与OpenAI的IPO筹备期发生重叠。
- 分析：通过梳理其投资标的（如Helion、Cerebras、Retro Biosciences）发现，这些公司频繁与OpenAI达成业务合作，直接提升了Altman的个人财富。
- 监管：众议院 oversight 委员会介入调查，SEC审查呼声高涨。
- 公司立场：董事会声称已披露并管理相关风险。
关键信息
- 关键数据：
- Retro Biosciences持股估值：2.58亿美元（2025年12月）。
- Helion持股估值：超41亿美元。
- Cerebras投资增长：6倍以上。
- 行业板块：核聚变能源、生物技术、AI算力芯片。
- 涉及公司：OpenAI, Helion, Cerebras, Retro Biosciences, SoftBank, Thrive Capital。
核心问题与回答
- 问题：Altman的个人投资是否与OpenAI存在不当利益输送？
- 回答：文章指出大量证据显示双方合作对Altman持股公司估值产生正面影响，引发了外界关于“自我交易”的质疑。董事会虽称披露透明，但其非直接持股的特殊机制使利益驱动问题变得复杂化。
正文
OpenAI CEO’s holdings in Helion and other companies have seen significant upswings since the AI giant explored or sealed tie-ups with Altman-linked startups
Much of Sam Altman’s wealth is tied up in a vast network of tech companies that include everything from nuclear fusion to a startup trying to create a new city on the Mediterranean.
A growing number of them have entered into business partnerships with OpenAI, creating a web of investments that are receiving scrutiny ahead of the company’s planned IPO. Last month, the House Oversight Committee launched a probe into Altman’s potential conflicts, and several attorneys general called for a Securities and Exchange Commission review.
Altman doesn’t own any direct equity in OpenAI, creating an unusual situation in which his financial motives aren’t tied to the company he runs.
The Wall Street Journal identified dozens of his investments and analyzed the impact of some deals on his wealth.
Sam Altman said at an event three years ago that he had roughly 400 active startup investments. The Journal identified more than 80, based on publicly-available materials and reporting, many of which date back to his time running the venture firm Y Combinator.
Many are in sectors that are closely tied to the AI boom, including software, biotechnology and energy.
At least 10 of the companies Altman has personally invested in also have, or have recently discussed, a business deal with OpenAI, the Journal found.
OpenAI entered into research partnerships with at least two biotechnology companies after Altman invested in them.
His stake in one of them, a life-extension startup called Retro Biosciences, was worth $258 million as of December, according to evidence presented in a federal trial last month brought by Elon Musk against OpenAI.
Altman has been an investor in the chip-maker Cerebras for almost a decade.
OpenAI recently agreed to buy its chips. The deal helped Cerebras mount a wildly-successful IPO, boosting Altman’s stake from December by more than sixfold.
Chief executives of public companies are typically discouraged by their board of directors from taking large stakes in outside ventures. The concern is that they will be incentivized to strike deals that help the companies they own, or expose themselves to allegations of self-dealing.
OpenAI board chairman Bret Taylor has said that Altman has been transparent in disclosing his involvement in other ventures, and that the company carefully manages potential conflicts.
Helion partnership
One of Altman’s biggest investments is in Helion, a nuclear-fusion startup that he first backed while serving as president of Y Combinator. Helion claims it is close to producing commercial electricity but doesn’t publish its research, making its claims difficult to evaluate. Altman’s efforts to partner OpenAI with Helion have generated controversy inside the company.
20152015
2021’21
2024’24
2025’25
2026’26
2015
2021
2024
2025
2026
2026
Methodology
The Journal compiled information on companies in Sam Altman’s personal investment portfolio—and which of those companies have done or discussed business with OpenAI—from several sources, including staff reports, company materials and PitchBook, which tracks information on private markets. Court documents and other evidence from the recent OpenAI-Musk trial also disclosed the value of Altman’s stakes in Helion, Cerebras, Retro Biosciences and other startups as of December. Portfolio companies were removed from the analysis if the Journal found evidence that a company is no longer operational or if Altman no longer holds a stake in the company.
Photo: Jason Redmond/Agence France-Presse/Getty Images
Advertisement
Appeared in the June 24, 2026, print edition as ‘How Altman’s Personal Investments Benefit From Connections to OpenAI’.